Research Article
Efficacy of Contact Needle Therapy for Chemotherapy-Induced Peripheral Neuropathy
Table 1
Patient characteristics.
| ā | Case | ā | 1 | 2 | 3 | 4 | 5 | 6 |
| Age/sex | 70/F | 54/F | 66/M | 57/M | 66/M | 73/F | Performance status | 0 | 0 | 0 | 0 | 0 | 0 | Primary lesion | Colon | Breast | Colon | Colon | Colon | Colon | Chemotherapeutic agents | Oxaliplatin | Docetaxel paclitaxel | Oxaliplatin | Oxaliplatin | Oxaliplatin | Oxaliplatin | Regimen of chemotherapy | XELOX + Bev | DOC PAC | mFOLFOX | mFOLFOX + Bev | SOX + Bev FOLFIRI + Bev | XEROX + Bev | Past operations | Yes | Yes | Yes | Yes | Yes | Yes | Tumor-baring | Yes | No | Yes | Yes | Yes | Yes |
|
|
XELOX: oxaliplatin, capesitabine. Bev: bevacizumab. SOX: oxaliplatin, S-1. FOLFIRI: folinic acid, fluorouracil, irinotecan. FOLFOX: folinic acid, acid, fluorouracil, oxaliplatin. DOC: fluorouracil, epirubicin, cyclophosphamide, docetaxel. PAC: paclitaxel, cyclophosphamide, doxorubicin.
|